Clinical Trial IB1001-202: UK Recruitment

IntraBio Inc. is pleased to confirm that the Clinical Trial IB1001-202, “ Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multi-center, open-label, rater-blinded Phase II study” is open for recruitment in the United Kingdom. IB1001-202 is a multinational study that investigates the effects of the novel drug IB1001 (N-Acetyl-L-Leucine) for treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff). IB1001-202 has previously been accepted by Independent Ethics Committees, and the UK Medicines and Healthcare products Regulatory Agency (EudraCT: 2018-004406-25), as well as National Regulatory Agencies in Germany and Spain, and the US Food and Drug Administration (IND 142302). In the UK/Europe, patients aged 6 and older with a genetically confirmed diagnosis of GM2 Gangliosidosis may be eligible for recruitment. The trial will consist of three study phases: a baseline period, a 6-week treatment period, and a 6-week post-treatment washout period, followed by a planned one-year extension phase. Patients (and a caregiver) will be reimbursed for reasonable out-of-pocket expenses incurred for participating in the trial, such as travel and parking. Two trial sites have been established in the United Kingdom for pediatric (ages 6-17) and adult (aged 18+) patients. Patients and families who are interested in learning more about the trial, including the eligibility criteria and enrollment process, should contact their prospective study site: Royal Manchester Children’s Hospital Trial Site for Patients Aged 6 – 17 Years Principal Investigator: Simon Jones, MD Contact: Laura Crowther, Clinical Trials Manager Email: [email protected] Tel: +44 161 701 9137 Salford Royal NHS Foundation Trust Trial Site for Patients Aged 18 Years + Principal Investigator: Reena Sharma, MD Contact: Marie Meehan, Senior Clinical Research Practitioner/ Team Manager Email: [email protected] Tel: +44 161 206 4192 For the complete enrollment criteria, as well as details regarding the study assessments, multinational clinical trial sites, etc., please visit ClinicalTrials.Gov(NCT03759665)

The release as fetched from its publisher. intrabio.com ↗